Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly and Company’s (NYSE:LLY) Mounjaro and Zepbound drugs are proving effective in helping patients lose weight, attracting billions of dollars in revenues. Mounjaro revenue more than doubled to ...